CHAIR
:
SPEAKER
(S):
Daniel Grau, Senior Vice President, Commercial Operations, CombinatoRx, Incorporated
Robert Beall, PhD, President and CEO, Cystic Fibrosis Foundation
Philippe Tinmouth, Senior Director, Vertex Pharmaceuticals, Inc.
Robert Gallotto, Vice President, Strategic Planning and Alliance Management, Altus Pharmaceuticals
Claudia Hirawat, Senior Vice President, Corporate Development, PTC Therapeutics
Description
Biotechnology companies and disease foundations are an obvious match, but both foundations and biotechnology companies are becoming more sophisticated in what they expect from these partnerships.
Objectives:
Learn how to identify common ground given two different motivations, one economic and one humanitarian.
Find out how to balance the risk at stages of development: when should the foundation invest and when should the company invest.
Discover how to manage an alliance given the unpredictability of science and inevitable departures from original R&D plans.